Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feigelson, H. S.
Right arrow Articles by Trichopoulos, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feigelson, H. S.
Right arrow Articles by Trichopoulos, D.
[Cancer Research 66, 2468-2475, February 15, 2006]
© 2006 American Association for Cancer Research


Epidemiology and Prevention

Haplotype Analysis of the HSD17B1 Gene and Risk of Breast Cancer: A Comprehensive Approach to Multicenter Analyses of Prospective Cohort Studies

Heather Spencer Feigelson1, David G. Cox2, Howard M. Cann6, Sholom Wacholder7, Rudolf Kaaks8, Brian E. Henderson10, Demetrius Albanes7, David Altshuler12, Goran Berglund14, Franco Berrino15, Sheila Bingham16, Julie E. Buring2,4, Noel P. Burtt12, Eugenia E. Calle1, Stephen J. Chanock17, Francoise Clavel-Chapelon18, Graham Colditz2,5, W. Ryan Diver1, Matthew L. Freedman13, Christopher A. Haiman10, Susan E. Hankinson2,5, Richard B. Hayes4, Joel N. Hirschhorn12, David Hunter2,5, Laurence N. Kolonel19, Peter Kraft3, Loic LeMarchand19, Jakob Linseisen20, William Modi17, Carmen Navarro21, Petra H. Peeters22, Malcolm C. Pike10, Elio Riboli9, V. Wendy Setiawan10, Daniel O. Stram11, Gilles Thomas6, Michael J. Thun1, Anne Tjonneland23 and Dimitrios Trichopoulos24

1 Department of Epidemiology and Surveillance Research, American Cancer Society, National Home Office, Atlanta, Georgia; 2 Department of Epidemiology and 3 Program in Molecular and Genetic Epidemiology, Harvard School of Public Health; 4 Division of Preventive Medicine and 5 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 6 Foundation Jean Dausset, CEPH, Paris, France; 7 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 8 Hormones and Cancer Group and 9 Unit of Nutrition and Cancer, IARC, Lyon, France; 10 Keck School of Medicine and 11 Division of Biostatistics and Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 12 Broad Institute at Harvard and Massachusetts Institute of Technology; 13 Whitehead Institute for Biomedical Research, Cambridge, Massachusetts; 14 Department of Medicine, Lund University, Malmö, Sweden; 15 Epidemiology Unit, National Cancer Institute, Milan, Italy; 16 Medical Research Council Dunn Nutrition Unit, Cambridge, United Kingdom; 17 Core Genotyping Facility, National Cancer Institute, Gaithersburg, Maryland; 18 Institut National de la Sante et de la Recherche Medicale, Institut Gustave Roussy, Villejuif, France; 19 Cancer Research Center, University of Hawaii, Honolulu, Hawaii; 20 Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany; 21 Epidemiology Department, Murcia Health Council, Murcia, Spain; 22 Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands; 23 Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; and 24 Department of Hygiene and Epidemiology, University of Athens Medical School, Athens, Greece

Requests for reprints: Heather Spencer Feigelson, Department of Epidemiology and Surveillance Research, American Cancer Society, 1599 Clifton Road Northeast, Atlanta, GA 30329. Phone: 404-929-6815; Fax: 404-327-6450; E-mail: heather.feigelson{at}cancer.org.

The 17ß-hydroxysteroid dehydrogenase 1 gene (HSD17B1) encodes 17HSD1, which catalyzes the final step of estradiol biosynthesis. Despite the important role of HSD17B1 in hormone metabolism, few epidemiologic studies of HSD17B1 and breast cancer have been conducted. This study includes 5,370 breast cancer cases and 7,480 matched controls from five large cohorts in the Breast and Prostate Cancer Cohort Consortium. We characterized variation in HSD17B1 by resequencing and dense genotyping a multiethnic sample and identified haplotype-tagging single nucleotide polymorphisms (htSNP) that capture common variation within a 33.3-kb region around HSD17B1. Four htSNPs, including the previously studied SNP rs605059 (S312G), were genotyped to tag five common haplotypes in all cases and controls. Conditional logistic regression was used to estimate odds ratios (OR) for disease. We found no evidence of association between common HSD17B1 haplotypes or htSNPs and overall risk of breast cancer. The OR for each haplotype relative to the most common haplotype ranged from 0.98 to 1.07 (omnibus test for association: X2 = 3.77, P = 0.58, 5 degrees of freedom). When cases were subdivided by estrogen receptor (ER) status, two common haplotypes were associated with ER-negative tumors (test for trend, Ps = 0.0009 and 0.0076; n = 353 cases). HSD17B1 variants that are common in Caucasians are not associated with overall risk of breast cancer; however, there was an association among the subset of ER-negative tumors. Although the probability that these ER-negative findings are false-positive results is high, these findings were consistent across each cohort examined and warrant further study. (Cancer Res 2006; 66(4): 2468-75)




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. M. Gaudet, S. Chanock, A. Dunning, K. Driver, L. A. Brinton, J. Lissowska, B. Peplonska, P. Pharoah, and M. Garcia-Closas
HSD17B1 Genetic Variants and Hormone Receptor-Defined Breast Cancer
Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2766 - 2772.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
M. Hamaguchi, M. Nishio, T. Toyama, H. Sugiura, N. Kondo, Y. Fujii, and H. Yamashita
Possible Difference in Frequencies of Genetic Polymorphisms of Estrogen Receptor {alpha}, Estrogen Metabolism and P53 Genes Between Estrogen Receptor-positive and -negative Breast Cancers
Jpn. J. Clin. Oncol., September 26, 2008; (2008) hyn097v1.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. I. Phipps, K. E. Malone, P. L. Porter, J. R. Daling, and C. I. Li
Body Size and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer in Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2078 - 2086.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Zhao, L.-E Wang, D. Li, R. M. Chamberlain, E. M. Sturgis, and Q. Wei
Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis
Carcinogenesis, August 1, 2008; 29(8): 1560 - 1566.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. C. Sakoda, C. Blackston, J. A. Doherty, R. M. Ray, M. G. Lin, H. Stalsberg, D. L. Gao, Z. Feng, D. B. Thomas, and C. Chen
Polymorphisms in Steroid Hormone Biosynthesis Genes and Risk of Breast Cancer and Fibrocystic Breast Conditions in Chinese Women
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1066 - 1073.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Editor's Note
Cancer Res., May 1, 2008; 68(9): 3550 - 3550.
[Full Text] [PDF]


Home page
J Mol EndocrinolHome page
M. Plourde, C. Manhes, G. Leblanc, F. Durocher, M. Dumont, O. Sinilnikova, I. BRCAs, and J. Simard
Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer
J. Mol. Endocrinol., April 1, 2008; 40(4): 161 - 172.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
V. W. Setiawan, F. R. Schumacher, C. A. Haiman, D. O. Stram, D. Albanes, D. Altshuler, G. Berglund, J. Buring, E. E. Calle, F. Clavel-Chapelon, et al.
CYP17 Genetic Variation and Risk of Breast and Prostate Cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2237 - 2246.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C. M. Dallal, J. Sullivan-Halley, R. K. Ross, Y. Wang, D. Deapen, P. L. Horn-Ross, P. Reynolds, D. O. Stram, C. A. Clarke, H. Anton-Culver, et al.
Long-term Recreational Physical Activity and Risk of Invasive and In Situ Breast Cancer: The California Teachers Study
Arch Intern Med, February 26, 2007; 167(4): 408 - 415.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. P. A. Ioannidis
Common genetic variants for breast cancer: 32 largely refuted candidates and larger prospects.
J Natl Cancer Inst, October 4, 2006; 98(19): 1350 - 1353.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.